By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Agendia said today that it has hired Ferrer inCode to distribute its MammaPrint breast cancer diagnostic test in Latin America.

The MammaPrint test is used to identify patients who are at high risk of early metastasis and who are likely to develop metastases within five years after surgery.

Ferrer inCode is a subsidiary of Spain's Grupo Ferrer Internacional that is focused on personalized medicine, genomics, proteomics, and other related technologies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.